Nanotechnology-Driven Bioavailability Enhancement: A Critical Review of BCS Class II and IV Drugs. Journal of Drug Discovery and Health Sciences, [S. l.], v. 3, n. 03, p. 63–71, 2026. DOI: 10.21590/d40skq78. Disponível em: https://jddhs.com/index.php/jddhs/article/view/146.. Acesso em: 17 sep. 2026.